Inhibikase Therapeutics, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

ATM Program (Additional Information) (Details) - Common Stock - USD ($)			1 Months Ended	12 Months Ended
	Jun. 20, 2025	Feb. 01, 2024	Feb. 28, 2026	Dec. 31, 2025
Wainwright Agreement \| H.C. Wainwright & Co., LLC
Marketable Securities [Line Items]
Sale of Stock, Consideration Received Per Transaction		$ 5,659,255
Common stock Aggregate offering price		50,000
ATM Agreement \| H.C. Wainwright & Co., LLC
Marketable Securities [Line Items]
Common stock Aggregate offering price		$ 849,187
Number of common stock sold		315,338
Jefferies Agreement \| Jefferies LLC
Marketable Securities [Line Items]
Sale of Stock, Consideration Received Per Transaction	$ 185,000,000
Number of common stock sold				0
Subsequent Event \| Jefferies Agreement \| Jefferies LLC
Marketable Securities [Line Items]
Sale of Stock, Consideration Received Per Transaction			$ 3,000,000
Number of common stock sold			1,904,762